Nuvation Bio Presents at Citigroup Biopharma Back to School Summit 2026
Nuvation Bio’s CEO and CFO discussed the company’s ROS1 TKI IBTROZI, highlighting that it received FDA approval a little over a year ago and that the launch has been strong. Management said IBTROZI is the number one ROS1 TKI in the market, with an over-4-year duration of response, a tolerable safety profile, very low discontinuation, and strong CNS control for brain-involved disease.